Navigation Links
Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
Date:9/21/2007

abine 1,250mg/m(squared), given by 30 minute intravenous infusion, on days 1 and 8 of each 21 day cycle.

The four week schedule used gemcitabine 1,000mg/m(squared), given by 30 minute intravenous infusion, on days 1, 8, and 15 of each 28 day cycle.

Cisplatin has been used at doses between 75-100mg/m(squared) once every 3 or 4 weeks.

Non-Small Cell Lung Cancer - Single-Agent Use

The recommended dose of gemcitabine is 1,000mg/m(squared), given by 30 minute intravenous infusion. This dose should be repeated once weekly for three weeks, followed by a one week rest period. This four week cycle is then repeated.

Pancreatic Cancer

The recommended dose of gemcitabine is 1,000mg/m(squared), given by 30 minute intravenous infusion. This dose should be repeated once weekly for up to 7 weeks, followed by a week of rest. Subsequent cycles consist of once weekly injections for 3 consecutive weeks out of every 4 weeks.

Bladder Cancer - Combination Use

The recommended dose for gemcitabine is 1,000mg/m(squared), given by 30 minute infusion. The dose should be given on days 1, 8, and 15 of each 28 day cycle in combination with cisplatin. Cisplatin is given at a recommended dose of 70mg/m(squared) on day 1 following gemcitabine or day 2 of each 28 day cycle. This four week cycle is then repeated.

Breast Cancer - Combination Use

The recommended regime is paclitaxel (175mg/m(squared)) on day 1 over 3 hours as an IV infusion, followed by gemcitabine (1,250mg/m(squared)) as a 30- 60 minute infusion on days 1 and 8 of each 21 day cycle. Patients should have an absolute granulocyte count of at least 1,500 (x 106/l) prior to initiation of the combination.

Gemcitabine can be administered on an outpatient basis.

Dosage reduction is based upon the amount of toxicity experienced by the patient. Patients receiving gemcitabine should be monitored prior to each dose for platelet, leucocyte, and granulocyte counts and, if necess
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer Treatment
2. Making Science Personal: Lilly Oncology to Unveil 76 Studies at ASCO 2007
3. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
4. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
5. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
6. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
7. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
8. Malvern initiates European user group meetings for chemical imaging
9. PARI Pharma Presents Study Results of Sinus Delivery and Inhaled Liposomal Ciclosporin A at European Cystic Fibrosis Conference
10. Targeted Genetics Reports Inflammatory Arthritis Clinical Data at European Rheumatology Conference
11. Can-Fite Proceeds with Development of Third Drug; Progress in Development of CF502 Will Be Presented at the Annual European Congress of Rheumatology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... 31, 2014 Mast Therapeutics, Inc. (NYSE MKT: ... for the quarter ended September 30, 2014. ... said:  "The third quarter was productive for Mast. Consistent with ... MST-188 for sickle cell disease is on track to ... have opened 50 study sites in the U.S. and ...
(Date:10/31/2014)... October 31, 2014 Oramed ... pharmaceutical company focused on the development of oral ... host a conference call to discuss the clinical ... ORMD-0801, the company,s proprietary oral insulin capsules, to ... 2014 at 10:00 a.m. Eastern time. ...
(Date:10/31/2014)... Investor-Edge has initiated coverage on the following ... Pharmaceuticals Inc. (NASDAQ: ISIS ), Halozyme Therapeutics ... (NASDAQ: ACAD ), and Synta Pharmaceuticals Corporation ... be accessed at: http://investor-edge.com/register . On ... 4,566.14, up 0.37%, the Dow Jones Industrial Average advanced ...
Breaking Medicine Technology:Mast Therapeutics Reports Third Quarter 2014 Financial Results 2Mast Therapeutics Reports Third Quarter 2014 Financial Results 3Mast Therapeutics Reports Third Quarter 2014 Financial Results 4Mast Therapeutics Reports Third Quarter 2014 Financial Results 5Mast Therapeutics Reports Third Quarter 2014 Financial Results 6Mast Therapeutics Reports Third Quarter 2014 Financial Results 7Mast Therapeutics Reports Third Quarter 2014 Financial Results 8Oramed to Report Key Top Line Results from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed to Report Key Top Line Results from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 2Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 3Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 4Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 5
(Date:10/31/2014)... 31, 2014 Monica Williams-Murphy MD ... all too well the chaos that can occur for ... “The vast majority of Americans who come into the ... are completely unprepared for the moment and so are ... can serve as a catalyst for a family to ...
(Date:10/31/2014)... With all the preparations families carry ... they may overlook one critical area – the potential ... school performance and even behavior. Typical children’s vision screenings ... progressive vision problems, and to address this challenge, Dr. ... initiative: The Awesome Eyes Student Vision Program. , ...
(Date:10/31/2014)... 2014 (HealthDay News) -- Surgery for low back pain ... the United States you live, a new report says. ... back pain at some point in their lives, and ... care for a spine problem," co-author Brook Martin, of ... said in a college news release. In spinal ...
(Date:10/31/2014)... of treatment and cost, patients with early stage ... irradiation (APBI) with proton therapy versus whole breast ... University of Texas MD Anderson Proton Therapy Center. ... based on typical patient characteristics, researchers used Medicare ... different types of partial and whole breast irradiation ...
(Date:10/31/2014)... a lab device to give cancer researchers an unprecedented ... cells spread through the body, causing more than 90 ... how tumor cells travel, the device could uncover new ... from the university,s Whiting School of Engineering and its ... their new system recently in the journal Cancer ...
Breaking Medicine News(10 mins):Health News:This Thanksgiving or Christmas Family Gathering, Use The New App ListStuffFast to Start "The Conversation" With a Parent That Has No Plan For End-of-Life 2Health News:This Thanksgiving or Christmas Family Gathering, Use The New App ListStuffFast to Start "The Conversation" With a Parent That Has No Plan For End-of-Life 3Health News:New School Vision Initiative Announced by Dr. Rosenak’s Optical Options; Program Aims to Help Recognize Unseen Vision Problems That Impact School Success 2Health News:New School Vision Initiative Announced by Dr. Rosenak’s Optical Options; Program Aims to Help Recognize Unseen Vision Problems That Impact School Success 3Health News:Spinal Surgery Varies by Region in U.S.: Study 2Health News:Proton therapy shown to be less costly than some alternative radiotherapy techniques 2Health News:Proton therapy shown to be less costly than some alternative radiotherapy techniques 3Health News:Viewing cancer on the move: New device yields close-up look at metastasis 2Health News:Viewing cancer on the move: New device yields close-up look at metastasis 3
... dose to the breast and lungs before deciding which CT ... new study cautions. The study compared organ doses to ... found a change in protocol could decrease breast radiation dose ... breast skin and parenchyma were found with our standard thoracic ...
... or anxiety states are often associated with disturbances ... are compounds that are released from the synapses ... of neighboring neurons. Thus, as their name suggests, ... serotonin transporter (SERT) is responsible for reuptake of ...
... PROVIDENCE, R.I. Peter J. Snyder, Ph.D., vice president ... 10 Ig Nobel Prize awards during the annual ceremony ... and colleagues from the University of Melbourne and Yale Medical ... acute urge to void the bladder can have the same ...
... at least on the healthy part. "Early to bed and early ... youths keep slimmer and more physically active than their night-owl peers, ... A study in the Oct. 1 issue of the journal ... participants, ages 9 to 16, and compared their weights and uses ...
... New America Media (NAM) have selected 16 reporters for ... in its second year. They represent a wide range of mainstream ... Arizona to Korea Daily Atlanta. The fellows will convene during ... to 22 in Boston and tap into over 500 presentations ...
... -- Working rotating shifts is not as potentially unhealthy ... research that suggests modern shift patterns may not carry ... shift schedules. "Recent research has suggested shift work ... mechanism responsible for this observation is still unknown," the ...
Cached Medicine News:Health News:Combating mood disorders 2Health News:Lifespan researcher wins Ig Nobel Prize 2Health News:Early to bed and early to rise -- study suggests it's keeping kids leaner 2Health News:Journalism fellows promise in-depth portrayal of aging in a diverse America 2Health News:Journalism fellows promise in-depth portrayal of aging in a diverse America 3Health News:Journalism fellows promise in-depth portrayal of aging in a diverse America 4Health News:Modern Shift Work Patterns May Be Less Harmful to Health 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: